# Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

> **NCT01555892** · PHASE1 · RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 136 (estimated)

## Conditions studied

- Hodgkin's Disease
- Non-Hodgkin's Lymphoma
- Lymphoproliferative Disease
- Lymphoma

## Interventions

- **BIOLOGICAL:** EBV-specific T cells: A
- **BIOLOGICAL:** EBV-specific T cells: B

## Key facts

- **NCT ID:** NCT01555892
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2013-01-14
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01555892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01555892, "Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01555892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*